Search
Illumina, Inc. has announced its intention to acquire SomaLogic, Inc. and its associated assets for a cash consideration of $350 million, with the potential for an additional $75 million in performance-based incentives and royalties. This strategic move aims to reinforce Illumina's presence in the proteomics market and propel its multi-omics strategy forward. By integrating SomaLogic's technology with Illumina's advanced high-throughput sequencing platforms, the company seeks to elevate product value and expedite technological advancements. SomaLogic, boasting a workforce of 250 and a CLIA and CAP-accredited laboratory in Colorado, anticipates achieving non-GAAP profitability by 2027. The transaction, which is contingent upon regulatory approvals, is expected to be finalized in the first half of 2026.
-
C114 Communication Network -
Communication Home
